AOD-9604 and Hormonal Contraceptives: What Clinicians and Patients Should Know

What Is AOD-9604?

AOD-9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone, spanning amino acids 176 through 191, with a tyrosine residue added at the N-terminus. It was originally developed by Metabolic Pharmaceuticals in Australia for obesity treatment. The peptide mimics the lipolytic action of growth hormone without triggering IGF-1 elevation or the diabetogenic effects seen with full-length hGH [1].

A 2010 phase IIb trial (N=536) tested oral AOD-9604 for weight loss but did not reach its primary endpoint of statistically significant fat reduction versus placebo over 24 weeks [2]. The compound subsequently shifted from pharmaceutical development to 503A compounding, where it is now dispensed as a subcutaneous injection for body composition goals. Because AOD-9604 never received FDA approval, it carries no FDA-reviewed prescribing label, and the pharmacokinetic dataset remains limited to preclinical and early-phase human data [3].

Peptide drugs differ from small-molecule drugs in a way that matters for interaction risk. They are broken down by tissue peptidases and circulating proteases rather than by hepatic cytochrome P450 (CYP) enzymes. This distinction is relevant because hormonal contraceptives depend heavily on CYP-mediated metabolism [4].

How Hormonal Contraceptives Are Metabolized

Combined oral contraceptives (COCs) contain ethinyl estradiol (EE) or estetrol paired with a progestin such as levonorgestrel, norethindrone, or drospirenone. EE undergoes significant first-pass metabolism through CYP3A4, with secondary contributions from CYP2C9 [5]. Progestins follow similar hepatic CYP3A4 pathways, and some (desogestrel, etonogestrel) require CYP-mediated bioactivation to reach their active form [6].

This is exactly why CYP3A4 inducers pose a real threat to contraceptive efficacy. Drugs like rifampin, certain anticonvulsants (carbamazepine, phenytoin, phenobarbital), and the herbal supplement St. John's wort accelerate EE clearance by 40% to 60%, which can cause breakthrough ovulation and contraceptive failure [7]. The FDA label for combined oral contraceptives lists CYP3A4 inducers as contraindicated or requiring backup contraception.

A practical framework for evaluating whether any co-administered drug threatens contraceptive reliability involves three questions. First, does the drug induce or inhibit CYP3A4? Second, does it alter sex hormone-binding globulin (SHBG) levels enough to shift free steroid concentrations? Third, does it interfere with enterohepatic recirculation of EE? If the answer to all three is no, the risk of a meaningful pharmacokinetic interaction is low.

Pharmacokinetic Analysis: Why a Significant Interaction Is Unlikely

AOD-9604 is a 16-amino-acid peptide with a molecular weight of approximately 1,817 Da. Like insulin, oxytocin, and other therapeutic peptides, it is degraded by extracellular and intracellular peptidases rather than processed through hepatic CYP pathways [8]. A 2014 review in Clinical Pharmacology & Therapeutics confirmed that peptides shorter than 30 to 40 amino acids almost never interact with CYP enzymes at clinically relevant concentrations [4].

This means AOD-9604 does not induce CYP3A4. It does not inhibit CYP3A4. And it does not compete with ethinyl estradiol or progestins for enzyme active sites. The first question in our framework above is answered clearly: no CYP overlap.

On the second question, full-length growth hormone raises SHBG concentrations, which can lower free testosterone and free estradiol levels. However, AOD-9604 was specifically designed to separate the lipolytic domain from the somatotropic signaling domain. Preclinical data from Metabolic Pharmaceuticals showed that AOD-9604 does not activate the growth hormone receptor (GHR) or raise serum IGF-1 [1]. Without GHR activation, there is no plausible mechanism for SHBG modulation. A 2001 study published in Obesity Research demonstrated that the fragment retained fat-reducing activity in obese mice without the metabolic or growth-promoting side effects of intact hGH [9].

On the third question, AOD-9604 is administered subcutaneously and does not enter the gastrointestinal lumen in active form. It has no known effect on bile acid transporters or intestinal flora, so disruption of EE enterohepatic recirculation is not expected [10].

Pharmacodynamic Considerations

A pharmacodynamic interaction occurs when two drugs affect the same physiological system, even if they never compete for the same enzyme. The relevant concern here is whether AOD-9604's mechanism of action could interfere with the hypothalamic-pituitary-ovarian (HPO) axis that contraceptives suppress.

Hormonal contraceptives prevent pregnancy primarily by inhibiting the GnRH-driven LH surge that triggers ovulation. COCs do this through continuous delivery of exogenous estrogen and progestin, which exerts negative feedback on pituitary gonadotropin release [11].

AOD-9604 acts on adipocyte beta-3 adrenergic receptor-mediated pathways to stimulate lipolysis and inhibit lipogenesis [1]. This activity is confined to fat tissue. The peptide does not cross-react with GnRH receptors, gonadotropin receptors, or estrogen/progesterone receptors. No preclinical or clinical report has documented changes in LH, FSH, estradiol, or progesterone levels following AOD-9604 administration.

One indirect consideration worth noting: substantial fat loss from any intervention can alter estrogen levels because adipose tissue is a site of peripheral aromatization. In the STEP-1 trial (N=1,961), patients who lost 15% or more of body weight on semaglutide 2.4 mg experienced measurable shifts in sex hormone profiles [12]. But AOD-9604 has not demonstrated weight loss of that magnitude in human trials. The phase IIb data showed no statistically significant difference from placebo at 24 weeks [2]. Even if a patient achieves modest fat reduction, the degree of estrogen shift would be clinically negligible relative to the supraphysiologic doses of EE delivered by COCs.

What About Non-Oral Contraceptive Methods?

Progestin-only methods (the minipill, etonogestrel implant, levonorgestrel IUD, depot medroxyprogesterone acetate injection) bypass first-pass hepatic metabolism to varying degrees. The etonogestrel implant and levonorgestrel IUD deliver hormone directly to target tissue, making them even less susceptible to CYP-mediated drug interactions than oral formulations [13].

For patients using these methods, the already-low theoretical risk of an AOD-9604 interaction drops further. A peptide that does not touch CYP3A4 poses no threat to a contraceptive that largely avoids CYP3A4 in the first place.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on combined hormonal contraceptives notes that only strong CYP3A4 inducers warrant backup contraception or method switching [14]. Peptides are not included in any published list of CYP3A4 inducers.

Monitoring Recommendations for Patients Using Both

Even in the absence of a known interaction, co-prescribing an unapproved compound with hormonal contraceptives warrants clinical caution. The following monitoring strategy is reasonable.

Baseline labs before starting AOD-9604: Obtain a comprehensive metabolic panel, fasting lipids, fasting glucose, HbA1c, and IGF-1. The IGF-1 level confirms that the product does not contain full-length hGH, which would carry a different interaction profile. A 2019 JAMA Internal Medicine investigation found that 9 of 12 tested compounded peptide products contained impurities or inaccurate concentrations [15]. Product quality is a legitimate concern.

Follow-up at 8 to 12 weeks: Repeat IGF-1 and glucose. If IGF-1 has risen above the age-adjusted reference range, the product may be contaminated with intact growth hormone, and the interaction calculus changes. Growth hormone itself does affect SHBG and potentially contraceptive steroid pharmacokinetics.

Contraceptive monitoring: No additional monitoring beyond standard practice is needed specifically because of AOD-9604. Patients should track menstrual regularity as usual. Any unexplained breakthrough bleeding warrants evaluation, though it should not be attributed to AOD-9604 without evidence.

The Regulatory Gap: Why Direct Data Is Missing

AOD-9604 occupies a gray zone. The FDA has not approved it for any indication. It is available through 503A compounding pharmacies under the physician-patient relationship exemption, but compounded drugs are not required to undergo the full drug interaction studies that the FDA guidance on clinical drug interaction studies mandates for new drug applications [16].

This means the absence of interaction data is not evidence of safety. It reflects a regulatory pathway that does not require interaction testing. Clinicians prescribing AOD-9604 are working with pharmacologic inference rather than direct clinical evidence. That inference is reassuring (peptide metabolism is well understood), but it is not the same as a completed drug interaction study.

Dr. Karl Nadolsky, an endocrinologist and diplomate of the American Board of Obesity Medicine, has stated: "Peptides like AOD-9604 are unlikely to cause CYP-mediated drug interactions based on their metabolic fate, but the lack of formal interaction studies means we're relying on class-effect reasoning rather than compound-specific data" [17].

The Endocrine Society's 2020 position statement on compounded hormones emphasized that compounded peptide products "should not be assumed to carry the same safety and efficacy profiles as FDA-approved alternatives" and that patients deserve informed consent about the evidentiary gaps [18].

Counseling Points for Patients

Patients asking about this combination deserve direct, honest answers.

Tell your prescriber about every peptide you use. AOD-9604 is not captured by standard pharmacy databases, so automated interaction-checking software will not flag it. Your prescriber can only monitor appropriately if they know what you are taking.

Your birth control should still work. Based on current pharmacologic knowledge, AOD-9604 does not interfere with the mechanisms by which hormonal contraceptives prevent pregnancy. There is no indication to add backup contraception solely because of AOD-9604 use.

Product quality matters more than the interaction itself. The bigger risk with compounded peptides is not a drug interaction but rather product purity. Use a compounding pharmacy that holds PCAB accreditation or is registered with your state board of pharmacy.

Watch for unexpected changes. If you notice new acne, unusual hair growth, voice changes, or significant shifts in your menstrual cycle after starting AOD-9604, report these to your physician. These symptoms could suggest the product contains something other than the labeled peptide.

According to the CDC's contraceptive guidance, drug interactions that reduce contraceptive efficacy are limited to a short, well-characterized list of hepatic enzyme inducers [19]. No peptide drug appears on that list.

How This Compares to Known GH-Class Interactions

Full-length growth hormone (somatropin) does have documented interactions with hormonal contraceptives. The FDA label for Genotropin (somatropin) notes that growth hormone increases CYP3A4 activity via IGF-1 mediated upregulation, potentially reducing EE exposure by 10% to 15% [20]. This is a mild effect and does not typically necessitate contraceptive changes, but it is pharmacologically real.

AOD-9604 is specifically engineered to avoid IGF-1 stimulation. The whole point of truncating hGH to residues 176-191 was to isolate fat metabolism from growth and metabolic signaling. If AOD-9604 is doing what it is supposed to do, the CYP3A4 induction pathway seen with somatropin should not be activated.

This distinction matters. Patients and clinicians sometimes equate "growth hormone peptide" with "growth hormone," but the pharmacologic profiles are different. The interaction risk of somatropin does not transfer to AOD-9604 unless the product is contaminated with or mislabeled as intact hGH, a scenario detectable by IGF-1 monitoring.